ArticleVaccine2010
Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- Review
- Progress and challenges associated with the development of ricin toxin subunit vaccines.Expert review of vaccines · 2016Review
- Enhancement of humoral immunity by the type II heat-labile enterotoxin LT-IIb is dependent upon IL-6 and neutrophils.Journal of leukocyte biology · 2016Article
- Recent advances in the development of vaccines against ricin.Human vaccines & immunotherapeutics · 2016Article
- Novel Ricin Subunit Antigens With Enhanced Capacity to Elicit Toxin-Neutralizing Antibody Responses in Mice.Journal of pharmaceutical sciences · 2016Article
- Strong protection against ricin challenge induced by a novel modified ricin A-chain protein in mouse model.Human vaccines & immunotherapeutics · 2015Article
- Differential neutralizing activities of a single domain camelid antibody (VHH) specific for ricin toxin's binding subunit (RTB).PloS one · 2014Article
- Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice.Clinical and vaccine immunology : CVI · 2013Article
- Near-infrared laser adjuvant for influenza vaccine.PloS one · 2013Article
- Article
- Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine.Clinical and vaccine immunology : CVI · 2012Article
- The need for continued development of ricin countermeasures.Advances in preventive medicine · 2012Article
- Immunity to ricin: fundamental insights into toxin-antibody interactions.Current topics in microbiology and immunology · 2012Review
- Review
- Structure of RiVax: a recombinant ricin vaccine.Acta crystallographica. Section D, Biological crystallography · 2011Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Ricin toxin is a CDC level B biothreat. We have developed a ricin vaccine, RiVax, which is a recombinant mutant of ricin A chain. RiVax is safe, immunogenic and protective in mice when administered intramuscularly (IM). We have now attempted to increase the utility and immunogenicity of RiVax by administering it intradermally (ID) with or without alum. Without alum, Rivax administered by the ID and IM routes was equally immunogenic and protective. With alum, ID vaccinations were more immunogenic and protective against both systemic and mucosal challenge with ricin and superior in protecting animals from ricin-induced lung damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.